- Home
- ATXS vs CVAC Comparison
ATXS vs CVAC Comparison
Compare ATXS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- CVAC
- Stock Information
- Founded
- ATXS 2008
- CVAC 2000
- Country
- ATXS United States
- CVAC Germany
- Employees
- ATXS N/A
- CVAC N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- CVAC Health Care
- Exchange
- ATXS Nasdaq
- CVAC Nasdaq
- Market Cap
- ATXS 401.2M
- CVAC 764.4M
- IPO Year
- ATXS 2015
- CVAC 2020
- Fundamental
- Price
- ATXS $5.81
- CVAC $5.39
- Analyst Decision
- ATXS Strong Buy
- CVAC Hold
- Analyst Count
- ATXS 7
- CVAC 3
- Target Price
- ATXS $32.43
- CVAC $6.83
- AVG Volume (30 Days)
- ATXS 370.5K
- CVAC 2.2M
- Earning Date
- ATXS 08-11-2025
- CVAC 08-14-2025
- Dividend Yield
- ATXS N/A
- CVAC N/A
- EPS Growth
- ATXS N/A
- CVAC N/A
- EPS
- ATXS N/A
- CVAC 0.87
- Revenue
- ATXS N/A
- CVAC $566,039,775.00
- Revenue This Year
- ATXS N/A
- CVAC N/A
- Revenue Next Year
- ATXS N/A
- CVAC $24.04
- P/E Ratio
- ATXS N/A
- CVAC $6.29
- Revenue Growth
- ATXS N/A
- CVAC 787.60
- 52 Week Low
- ATXS $3.56
- CVAC $2.37
- 52 Week High
- ATXS $12.92
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- ATXS 56.55
- CVAC 64.90
- Support Level
- ATXS $5.26
- CVAC $5.33
- Resistance Level
- ATXS $5.79
- CVAC $5.58
- Average True Range (ATR)
- ATXS 0.38
- CVAC 0.09
- MACD
- ATXS -0.04
- CVAC -0.05
- Stochastic Oscillator
- ATXS 52.27
- CVAC 29.17
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.